Overview

A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC

Status:
Suspended

Trial end date:
2020-07-30

Target enrollment:

Participant gender:

Summary

This multicenter, randomized, double-blind study will evaluate the efficacy, safety of JS001 administered with nab-paclitaxel compared with placebo in combination with nab-paclitaxel as first-line therapy in participants with primarily diagnosed stage IV and recurrent or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).

Phase:

Phase 3

Details

Lead Sponsor:

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Collaborator:

TopAlliance Biosciences, Inc.

Treatments:

Albumin-Bound Paclitaxel
Antibodies
Immunoglobulins
Paclitaxel